Real-World Stability Confirmed for Biosimilar Ximluci in Prefilled Syringes

Analysis Highlights Fiscal, Access Benefits of Omalizumab Biosimilars in Europe

September 30th 2025

By Skylar Jeremias

Omalizumab biosimilars promise significant savings for European health systems, enhancing access to vital therapies for patients with severe allergies.

Biosimilar Tocilizumab Shows Cost-Effectiveness Advantage in Spanish RA Population

September 29th 2025

By Skylar Jeremias

Biosimilar tocilizumab proves to be a cost-effective treatment for rheumatoid arthritis in Spain, enhancing access to advanced therapies.

The Top 5 Biosimilar Articles for the Week of September 22

September 26th 2025

By Skylar Jeremias

Here are the top 5 biosimilar articles for the week of September 22, 2025.

Eye on Pharma: Europe and MENA Region See Expanding Biosimilar Pipelines

September 25th 2025

By Skylar Jeremias

Major advancements in biosimilars emerge in Europe and Middle East and North Africa (MENA) region, enhancing patient access and affordability in critical therapeutic areas.

Biosimilars Drive Savings and Access, Yet Looming Development Gap Threatens Future

September 23rd 2025

By Skylar Jeremias

Biosimilars and generics drive significant health care savings, yet a concerning lack of biosimilar development for biologics set to lose exclusivity in the next 10 years threatens future access and affordability.

Stable Treatment Persistence in RA After Etanercept Biosimilar Introduction in Australia

September 23rd 2025

By Skylar Jeremias

Australia's adoption of etanercept biosimilars enhances access to rheumatoid arthritis treatments, maintaining treatment persistence and patient care quality.

Global Aflibercept Biosimilar Progress Signals Rising Access for Retinal Disease Care

September 22nd 2025

By Skylar Jeremias

Recent approvals and settlements enhance global access to aflibercept biosimilars, improving treatment options for age-related macular degeneration and diabetic retinopathy.

EC Approves New Biosimilars for Bone and Eye Conditions

September 19th 2025

By Skylar Jeremias

The European Commission (EC) approves new biosimilars for osteoporosis and eye conditions, enhancing treatment options and patient access across Europe.

FDA Approves Biocon Biologics' Denosumab Biosimilars: Bosaya and Aukelso

September 18th 2025

By Skylar Jeremias

The FDA has approved Bosaya and Aukelso, expanding affordable denosumab biosimilars for osteoporosis and bone-related cancers and enhancing treatment options.

BioRationality: No More Clinical Efficacy Testing for Biosimilars, Going From Biosimilars to Biogenerics

September 16th 2025

By Sarfaraz K. Niazi, PhD